The relationship between serum adropin levels and erectile dysfunction

Erectile dysfunction (ED) is associated with endothelial damage, especially atheroscle-rosis. The search for biomarkers that can predict ED still continues. Adropin is known to affect nitric oxide (NO) bioavailability and energy homeostasis. In our study, we have aimed to investigate the relationship between serum adropin levels and ED. Male patients with and without ED between 40–60 years of age, who presented to the outpatient clinics of urology between November 2019–February 2020, were prospectively included in the study. Biochemical values measured at the time of admission to the outpatient clinic. According to the International Index of Erectile Function-5 (IIEF-5) scores which range between 5 and 25 points, patients with a score ≤21 were considered to have ED. The patients were divided into two groups: as ED and non-ED control groups. Laboratory values obtained at admission to outpatient clinics of urology were compared between groups. Patients with (n: 40), and without (n: 40) ED were included in the study. The mean age (50.2 ± 5.7 years), average body mass index (BMI) (29.7 ± 2.5 kg/m2), IIEF score (15.8 ± 6 pts), serum adropin (584.8 ± 172 pg/mL), and total testosterone (396.4 ± 91.7 ng/dL) levels were recorded. Serum adropin and testosterone levels were statistically significantly higher in the non-ED group than in the ED group (712.3 ± 222 pg/mL vs. 511.1 ± 145 pg/mL, p < 0.001 and 420.5 ± 56 ng/dL vs. 374.3 ± 98 ng/dL, respectively p = 0.032). Whereas fasting blood glucose (FBG) values were found to be statistically significantly higher in the ED group (100.2 ± 14 mg/dL vs. 143.8 ± 78 mg/dL, p = 0.001). According to the results of our study, serum levels of adropin which improves endothelial functions were comparatively lower in ED patients, as expected.

Adropin; Biomarkers; Erectile dysfunction; Total testosterone

[1] Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Urology. 2010; 57: 804–814.

[2] Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nature Reviews Cardiology. 2022; 19: 59–74.

[3] Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology. 2022; 29: 5–15.

[4] Meakin PJ, Coull BM, Tuharska Z, McCaffery C, Akoumianakis I, Antoniades C, et al. Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction. Journal of Clinical Investigation. 2020; 130: 4104–4117.

[5] Si Y, Feng Z, Liu Y, Fan W, Shan W, Zhang Y, et al. Inflammatory biomarkers, angiogenesis and lymphangiogenesis in epicardial adipose tissue correlate with coronary artery disease. Scientific Reports. 2023; 13: 2831.

[6] Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metabolism. 2008; 8: 468–481.

[7] Kolben Y, Weksler‐Zangen S, Ilan Y. Adropin as a potential mediator of the metabolic system-autonomic nervous system-chronobiology axis: implementing a personalized signature-based platform for chronotherapy. Obesity Reviews. 2021; 22: e13108.

[8] Bozic J, Kumric M, Ticinovic Kurir T, Males I, Borovac JA, Martinovic D, et al. Role of adropin in cardiometabolic disorders: from pathophysiological mechanisms to therapeutic target. Biomedicines. 2021; 9: 1407.

[9] Soori R, Amini AA, Choobineh S, Eskandari A, Behjat A, Ghram A, et al. Exercise attenuates myocardial fibrosis and increases angiogenesis-related molecules in the myocardium of aged rats. Archives of Physiology and Biochemistry. 2022; 128: 1–6.

[10] Ali II, D’Souza C, Singh J, Adeghate E. Adropin’s role in energy homeostasis and metabolic disorders. International Journal of Molecular Sciences. 2022; 23: 8318.

[11] Altamimi TR, Gao S, Karwi QG, Fukushima A, Rawat S, Wagg CS, et al. Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism. 2019; 98: 37–48.

[12] Yang C, DeMars KM, Candelario-Jalil E. Age-dependent decrease in adropin is associated with reduced levels of endothelial nitric oxide synthase and increased oxidative stress in the rat brain. Aging and Disease. 2018; 9: 322.

[13] Yosaee S, Soltani S, Sekhavati E, Jazayeri S. Adropin-a novel biomarker of heart disease: a systematic review article. Iranian Journal of Public Health. 2016; 45: 1568–1576.

[14] Celik HT, Bilen M, Kazancı F, Yildirim ME, İncebay İB, Erdamar H. Serum adropin as a predictive biomarker of erectile dysfunction in coronary artery disease patients. Central European Journal of Urology. 2019; 72: 302–306.

[15] Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. International Journal of Molecular Sciences. 2018; 19: 1293.

[16] Zheng J, Liu M, Chen L, Yin F, Zhu X, Gou J, et al. Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis. Cardiovascular Diagnosis and Therapy. 2019; 9: 1–7.

[17] Muhammed AA, Eid RMHM, Mohammed WS, Abdel-Fadeil MR. An association between adropin hormone and total testosterone in obese men: a case-control study. BMC Endocrine Disorders. 2022; 22: 192.

[18] Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, et al. Serum adropin levels are reduced in adult patients with nonalcoholic fatty liver disease. Medical Principles and Practice. 2019; 28: 463–469.

[19] Zhang H, Jiang L, Yang YJ, Ge RK, Zhou M, Hu H, et al. Aerobic exercise improves endothelial function and serum adropin levels in obese adolescents independent of body weight loss. Scientific Reports. 2017; 7: 17717.

[20] Brnić D, Martinovic D, Zivkovic PM, Tokic D, Tadin Hadjina I, Rusic D, et al. Serum adropin levels are reduced in patients with inflammatory bowel diseases. Scientific Reports. 2020; 10: 9264.